Pharmaceutical companies have been able to request anticipated interventions for innovative medicines from the Inami since 2014. They can do so when they are treating a serious or fatal illness, and there are no alternatives. However, companies have not put in any requests since the system was launched, despite there being a budget of 7 million euros, the Het Nieuwsblad op Zondag revealed on Sunday. Companies can put in a request for an intervention before the medicine is registered or the reimbursement rules for the patient are fixed. By putting this procedure in place, the government hopes to give patients quicker access to innovative medicines.
However, after eight months, there have been no requests. “Apparently, pharmaceutical companies have decided to play the waiting game”, says Ri De Ridder from the Inami.
Jason Bennett (Source: Belga)